[
    [
        {
            "time": "",
            "original_text": "医疗保健：继续推荐3+2主线 荐2股",
            "features": {
                "keywords": [
                    "医疗保健",
                    "3+2主线",
                    "荐股"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医疗保健"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "医疗保健：继续推荐3+2主线 荐2股",
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "【国盛医药张金洋团队】详解2019Q1机构医药持仓，继续推荐医药流通",
            "features": {
                "keywords": [
                    "国盛医药",
                    "2019Q1",
                    "机构医药持仓",
                    "医药流通"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药流通"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【国盛医药张金洋团队】详解2019Q1机构医药持仓，继续推荐医药流通",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 5,
                "Market_Scope": 7,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 4
            }
        },
        {
            "time": "",
            "original_text": "【华泰医药代雯团队】乐普医疗(300003.SZ)一季报点评：业绩增长强劲，符合预期",
            "features": {
                "keywords": [
                    "华泰医药",
                    "乐普医疗",
                    "一季报",
                    "业绩增长",
                    "符合预期"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【华泰医药代雯团队】乐普医疗(300003.SZ)一季报点评：业绩增长强劲，符合预期",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        }
    ]
]